J&J and Abbott Labs Top Envestnet Asset Mgmnt’s Biggest Healthcare Investments

Wall St. Watchdog reveals information regarding Envestnet Asset Management’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 131 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $48.259 million.

Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Envestnet Asset Management reported holding 50,908 shares with a market value of $3,386,400. This comprised 0.09% of the total portfolio. On 09/30/2011, Envestnet Asset Management reported holding 65,726 shares with a market value of $4,186,089. This comprised 0.11% of the total portfolio. The net change in shares for this position over the two quarters is 14,818. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Abbott Laboratories (NYSE:ABT): On 06/30/2011, Envestnet Asset Management reported holding 42,516 shares with a market value of $2,237,192. This comprised 0.06% of the total portfolio. On 09/30/2011, Envestnet Asset Management reported holding 69,845 shares with a market value of $3,571,873. This comprised 0.1% of the total portfolio. The net change in shares for this position over the two quarters is 27,329. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.

Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Envestnet Asset Management reported holding 54,820 shares with a market value of $1,934,598. This comprised 0.05% of the total portfolio. On 09/30/2011, Envestnet Asset Management reported holding 59,940 shares with a market value of $1,960,038. This comprised 0.05% of the total portfolio. The net change in shares for this position over the two quarters is 5,120. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.

Pfizer Inc. (NYSE:PFE): On 06/30/2011, Envestnet Asset Management reported holding 107,980 shares with a market value of $2,224,388. This comprised 0.06% of the total portfolio. On 09/30/2011, Envestnet Asset Management reported holding 101,867 shares with a market value of $1,801,009. This comprised 0.05% of the total portfolio. The net change in shares for this position over the two quarters is -6,113. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.

Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, Envestnet Asset Management reported holding 36,051 shares with a market value of $1,859,511. This comprised 0.05% of the total portfolio. On 09/30/2011, Envestnet Asset Management reported holding 34,407 shares with a market value of $1,586,851. This comprised 0.04% of the total portfolio. The net change in shares for this position over the two quarters is -1,644. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.

Celgene Corporation (NASDAQ:CELG): On 06/30/2011, Envestnet Asset Management reported holding 24,522 shares with a market value of $1,479,167. This comprised 0.04% of the total portfolio. On 09/30/2011, Envestnet Asset Management reported holding 24,642 shares with a market value of $1,525,586. This comprised 0.04% of the total portfolio. The net change in shares for this position over the two quarters is 120. About Company: Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): On 06/30/2011, Envestnet Asset Management reported holding 51,248 shares with a market value of $2,471,179. This comprised 0.07% of the total portfolio. On 09/30/2011, Envestnet Asset Management reported holding 38,256 shares with a market value of $1,423,888. This comprised 0.04% of the total portfolio. The net change in shares for this position over the two quarters is -12,992. About Company: Teva Pharmaceutical Industries Ltd. develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis. Teva develops novel drugs for diseases of the central nervous system.

Novartis Ag (NYSE:NVS): On 06/30/2011, Envestnet Asset Management reported holding 25,396 shares with a market value of $1,551,950. This comprised 0.04% of the total portfolio. On 09/30/2011, Envestnet Asset Management reported holding 23,808 shares with a market value of $1,327,772. This comprised 0.04% of the total portfolio. The net change in shares for this position over the two quarters is -1,588. About Company: Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases; oncology, neuroscience, transplantation, dermatology, gastrointestinal and urinary conditions, and arthritis; vaccines and diagnostics; vision, and animal health products.

Fresenius Medical Care Ag & Co. Kgaa (NYSE:FMS): On 06/30/2011, Envestnet Asset Management reported holding 17,874 shares with a market value of $1,335,188. This comprised 0.04% of the total portfolio. On 09/30/2011, Envestnet Asset Management reported holding 19,152 shares with a market value of $1,293,335. This comprised 0.03% of the total portfolio. The net change in shares for this position over the two quarters is 1,278. About Company: Fresenius Medical Care AG & Co. KGaA offers kidney dialysis services and manufactures and distributes equipment and products used in the treatment of dialysis patients. The Company also offers clinical laboratory testing and diagnostic testing services and provides home infusion, respiratory therapy, ultrasound, and echo-cardiography. Fresenius operates worldwide.

Becton Dickinson And Company (NYSE:BDX): On 06/30/2011, Envestnet Asset Management reported holding 18,430 shares with a market value of $1,588,113. This comprised 0.04% of the total portfolio. On 09/30/2011, Envestnet Asset Management reported holding 17,073 shares with a market value of $1,251,792. This comprised 0.03% of the total portfolio. The net change in shares for this position over the two quarters is -1,357. About Company: Becton, Dickinson and Company manufactures and sells a variety of medical supplies and devices and diagnostic systems. The Company’s products are used by health care professionals, medical research institutions, and the general public. Becton’s products are marketed worldwide.

(Note: Data regarding Envestnet Asset Management’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

To contact the reporter on this story: Dave Friedman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com